DE69813571D1 - 11,15-o-dialkylprostaglandin-e-derivate, verfahren zu ihrer herstellung und arzneimittel, die diese als aktiven inhaltsstoff enthalten - Google Patents

11,15-o-dialkylprostaglandin-e-derivate, verfahren zu ihrer herstellung und arzneimittel, die diese als aktiven inhaltsstoff enthalten

Info

Publication number
DE69813571D1
DE69813571D1 DE69813571T DE69813571T DE69813571D1 DE 69813571 D1 DE69813571 D1 DE 69813571D1 DE 69813571 T DE69813571 T DE 69813571T DE 69813571 T DE69813571 T DE 69813571T DE 69813571 D1 DE69813571 D1 DE 69813571D1
Authority
DE
Germany
Prior art keywords
derivatives
active ingredient
dialkylprostaglandin
production
products containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69813571T
Other languages
English (en)
Other versions
DE69813571T2 (de
Inventor
Shuichi Ohuchida
Takayuki Maruyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Publication of DE69813571D1 publication Critical patent/DE69813571D1/de
Application granted granted Critical
Publication of DE69813571T2 publication Critical patent/DE69813571T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69813571T 1997-02-10 1998-02-10 11,15-o-dialkylprostaglandin-e-derivate, verfahren zu ihrer herstellung und arzneimittel, die diese als aktiven inhaltsstoff enthalten Expired - Fee Related DE69813571T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP4157197 1997-02-10
JP4157197 1997-02-10
PCT/JP1998/000544 WO1998034916A1 (fr) 1997-02-10 1998-02-10 Derives de 11,15-o-dialkylprostaglandine e, leur procede de production, et medicaments renfermant ceux-ci comme principe actif

Publications (2)

Publication Number Publication Date
DE69813571D1 true DE69813571D1 (de) 2003-05-22
DE69813571T2 DE69813571T2 (de) 2004-02-12

Family

ID=12612138

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69813571T Expired - Fee Related DE69813571T2 (de) 1997-02-10 1998-02-10 11,15-o-dialkylprostaglandin-e-derivate, verfahren zu ihrer herstellung und arzneimittel, die diese als aktiven inhaltsstoff enthalten

Country Status (10)

Country Link
US (1) US6288119B1 (de)
EP (1) EP1008588B1 (de)
JP (1) JP4044967B2 (de)
KR (1) KR20000070903A (de)
AT (1) ATE237587T1 (de)
DE (1) DE69813571T2 (de)
DK (1) DK1008588T3 (de)
ES (1) ES2196527T3 (de)
PT (1) PT1008588E (de)
WO (1) WO1998034916A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4834224B2 (ja) 1999-03-05 2011-12-14 デューク ユニバーシティ Ｃ１６不飽和ｆｐ−選択的プロスタグランジン類縁体
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
WO2004032964A1 (ja) * 2002-10-10 2004-04-22 Ono Pharmaceutical Co., Ltd. アレルギー性疾患治療剤
TW200413000A (en) 2002-10-10 2004-08-01 Ono Pharmaceutical Co Intrinsic repair factor producing accelerator
WO2004074842A2 (en) * 2003-02-24 2004-09-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep3 (prostaglandin e2 ep3)
US20070167403A1 (en) * 2003-04-03 2007-07-19 Yoshifumi Takenobu Remedy for spinal canal stenosis
EP2422814A1 (de) * 2003-07-25 2012-02-29 Ono Pharmaceutical Co., Ltd. Heilmittel für Knorpelerkrankungen
EP1707208A4 (de) * 2003-12-05 2010-03-17 Ono Pharmaceutical Co Blutflusspromotoren für cauda-equina-gewebe
EP1723132A1 (de) 2004-02-12 2006-11-22 Asterand Uk Limited Agonisten des ep2-rezeptors
AR056968A1 (es) * 2005-04-11 2007-11-07 Xenon Pharmaceuticals Inc Compuestos espiro-oxindol y composiciones farmacéuticas
AR053710A1 (es) * 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
EP2494990A1 (de) 2005-06-03 2012-09-05 Ono Pharmaceutical Co., Ltd. Wirkstoff zur Regenerierung und/oder zum Schutz von Nerven
EP1951701A2 (de) 2005-08-09 2008-08-06 Asterand Uk Limited Agonisten des ep2-rezeptors
HUE031972T2 (en) 2005-12-29 2017-08-28 Celtaxsys Inc Diamin derivatives as leukotriene A4 hydrolase inhibitors
TW200833695A (en) 2006-10-12 2008-08-16 Xenon Pharmaceuticals Inc Use of spiro-oxindole compounds as therapeutic agents
CL2007002953A1 (es) * 2006-10-12 2008-02-01 Xenon Pharmaceuticals Inc Compuestos derivados de espiro-oxindol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del dolor, cancer, prurito, hiperplasia prostatica benigna, hipercolesterolemia.
US20090124695A1 (en) 2007-11-14 2009-05-14 Cayman Chemical Company Prostaglandin e1 and e2 analogs for the treatment of various medical conditions
RU2011119626A (ru) * 2008-10-17 2012-11-27 Ксенон Фармасьютикалз Инк. Спирооксиндольные соединения и их применение в качестве терапевтичеких средств
US8101647B2 (en) * 2008-10-17 2012-01-24 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
US8623918B2 (en) 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
PL2441760T3 (pl) 2009-06-10 2014-05-30 Ono Pharmaceutical Co Związek o działaniu kurczącym mięsień-wypieracz i zwiotczającym mięsień-zwieracz cewki moczowej
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
WO2011047173A2 (en) 2009-10-14 2011-04-21 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
EP2488531B1 (de) * 2009-10-14 2014-03-26 Xenon Pharmaceuticals Inc. Verfahren zur herstellung von spiro-oxindol derivaten
WO2011106729A2 (en) 2010-02-26 2011-09-01 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
WO2013154712A1 (en) 2012-04-12 2013-10-17 Xenon Pharmaceuticals Inc. Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents
TWI597274B (zh) 2012-08-31 2017-09-01 小野藥品工業股份有限公司 胺鹽及其結晶
WO2014152229A2 (en) 2013-03-14 2014-09-25 Celtaxsys, Inc. Inhibitors of leukotriene a4 hydrolase
EP2818484A1 (de) 2013-06-28 2014-12-31 Universitat Autònoma de Barcelona Synergistische Kombination eines Anti-IgE-Antikörpers und eines EP2-Rezeptoragonisten
WO2016127068A1 (en) 2015-02-05 2016-08-11 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
WO2017218920A1 (en) 2016-06-16 2017-12-21 Teva Pharmaceuticals International Gmbh Asymmetric synthesis of funapide
JP7174700B2 (ja) 2016-12-09 2022-11-17 セルタクシー、エルエルシー ロイコトリエンａ４ヒドロラーゼの阻害剤としてのモノアミン及びモノアミン誘導体
JP7145154B2 (ja) 2016-12-09 2022-09-30 セルタクシー、エルエルシー ロイコトリエンａ４ヒドロラーゼの阻害剤
EP3551608A1 (de) 2016-12-09 2019-10-16 Celtaxsys Inc. Anhängende amine und derivate als inhibitoren der leukotrien-a4-hydrolase

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3835180A (en) * 1971-05-04 1974-09-10 Upjohn Co 15 alkoxy pge compounds
US3876690A (en) * 1973-05-11 1975-04-08 American Cyanamid Co 1-alkoxy-9-keto-prostenoic acid derivatives
GB1451798A (en) * 1973-08-02 1976-10-06 Ici Ltd Prostanoic acid derivatives
US4236027A (en) * 1977-10-17 1980-11-25 American Cyanamid Company Novel 11-alkoxy-9-keto (or hydroxy)-prostenoic acid derivatives and method for preparing same
JPS55115836A (en) * 1979-03-02 1980-09-06 Toray Ind Inc Preparation of methyl ether derivative
DE3510978A1 (de) * 1985-03-22 1986-09-25 Schering AG, Berlin und Bergkamen, 1000 Berlin Neue 9-halogenprostaglandine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JPH03101622A (ja) * 1989-09-11 1991-04-26 Green Cross Corp:The 肝炎予防治療剤

Also Published As

Publication number Publication date
US6288119B1 (en) 2001-09-11
EP1008588A1 (de) 2000-06-14
DK1008588T3 (da) 2003-07-28
WO1998034916A1 (fr) 1998-08-13
ES2196527T3 (es) 2003-12-16
JP4044967B2 (ja) 2008-02-06
KR20000070903A (ko) 2000-11-25
ATE237587T1 (de) 2003-05-15
PT1008588E (pt) 2003-09-30
EP1008588B1 (de) 2003-04-16
EP1008588A4 (de) 2000-06-14
DE69813571T2 (de) 2004-02-12

Similar Documents

Publication Publication Date Title
DE69813571D1 (de) 11,15-o-dialkylprostaglandin-e-derivate, verfahren zu ihrer herstellung und arzneimittel, die diese als aktiven inhaltsstoff enthalten
NL300175I1 (nl) Methylsulfonylfenyl-2-(5H)-furanonen als remmers van COX-2.
ATE260255T1 (de) 5-oxo-pyrrolidine-2-carbonsäure- hydroxamidderivate
MA27867A1 (fr) Nouveaux derives de 2h-pyridazine-3-one, compositions pharmaceutiques contenant ces derives et procede de preparation de l'ingredient actif.
EP1090908A3 (de) Cyclobutan-Derivate als Inhibitoren der Protein-Farnesyltransferase
NO974163L (no) Ester av 5-aminolevulinsyre som fotosensibiliserings-middel i fotokjemoterapi
MA27568A1 (fr) Derives de pyrrolopyrimidine
ATE264337T1 (de) Glucopyranosyloxypyrazol-derivate, diese enthaltende arzneimittel und zwischenprodukte zu deren herstellung
ATE321543T1 (de) Pharmazeutische zusammensetzungen mit hydroximsäurederivaten
EP1314719A4 (de) Benzoesäurederivate und medikamente die diese als aktiven wirkstoff enthalten
AU8811401A (en) Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient
MA26725A1 (fr) Derives de resorcinol, compositions pharmaceutiques les contenant et procede pour leur preparation
DE69600272D1 (de) Chinolin-4-carbonylguanidin-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
AU5879798A (en) Agents inhibiting progress of pterygium and postoperative recurrence of the same
HUP0004900A2 (hu) Mozgászavarok kezelésére szolgáló, hatóanyagként NMDA-receptor antagonista hatású piperidinszármazékokat tartalmazó gyógyszerkészítmények
WO2003080631A8 (en) Plasma carboxypeptidase b inhibitors
ATE303991T1 (de) Aralkyltetrahydropyridine, deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten
DE69217613D1 (de) Stickstoff enthaltende bizyklische Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
DE60234024D1 (de) Neue retinoidderivate und eine pharmazeutische anti-krebs-zusammensetzung, die diese verbindungen enthält
DK1179342T3 (da) Medicinske sammensætninger til öjeblikkelig frigivelse ved oral anvendelse
ATE267832T1 (de) Substanz gm-95, verfahren zu ihrer herstellung und ihre verwendung
MXPA04003200A (es) Nuevos compuestos de isoquinolina, un proceso para su preparacion y composiciones farmaceuticas que los contienen.
BR0109252A (pt) Composto, processo para produzir um composto, composição farmacêutica, e, uso de um composto ou de uma composição
ATE265459T1 (de) Triazolpurin-derivate, medikamentzusammensetzungen, die diese enthalten und mittel, die affinität zum adenosin a3 rezeptor zeigen
DE69528984T2 (de) Hemmung der leukotrienbiosynthese mittels harnstoffderivaten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee